EUVIMEDEUVIMED entdecken
Crossref

Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome - Program (ASSOP) Bloodstream Infection Annual Report 2022

Geoffrey W Coombs, Denise A Daley, Princy Shoby, Shakeel Mowlaboccus

Communicable Diseases Intelligence · 2023

DOI: 10.33321/cdi.2023.47.67 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2023. Verfasst von Geoffrey W Coombs und 3 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department o…. Hauptthemen laut MEDLINE: Staphylococcal Infections, Methicillin-Resistant Staphylococcus aureus, Bacteremia, Cross Infection. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From 1 January to 31 December 2022, fifty-five institutions across Australia participated in the Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP). The aim of ASSOP 2022 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that were antimicrobial resistant, with particular emphasis on susceptibility to methicillin and on characterisation of the molecular epidemiology of the methicillin-resistant isolates. A total of 3,214 SAB episodes were reported, of which 77.5% were community-onset. Overall, 15.0% of S. aureus were methicillin resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 21.4%, which was significantly different to the 16.8% all-cause mortality associated with methicillin-susceptible SAB (p = 0.02). With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin-susceptible S. aureus was rare. However, in addition to the β-lactams, approximately 31% of methicillin-resistant S. aureus (MRSA) were resistant to ciprofloxacin; 30% to erythromycin; 13% to tetracycline; 11% to gentamicin; and 2% to co-trimoxazole. One MRSA isolate, with a daptomycin MIC of 1.5 mg/L, harboured the A302V mprF and A23V cls2 mutations. When applying the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, teicoplanin resistance was detected in one MRSA isolate. Resistance to vancomycin or linezolid was not detected. Resistance to non-β-lactam antimicrobials was largely attributable to the healthcare-associated MRSA (HA-MRSA) clone ST22-IV [2B] (EMRSA-15), and to the community-associated MRSA (CA-MRSA) clone ST45-V [5C2&5] which has acquired resistance to multiple antimicrobials including ciprofloxacin, clindamycin, erythromycin, gentamicin, and tetracycline. The ST22-IV [2B] (EMRSA-15) clone is the predominant HA-MRSA clone in Australia. Nonetheless, 86% of methicillin-resistant SAB episodes were due to CA-MRSA clones. Although polyclonal, approximately 72% of CA-MRSA clones were characterised as ST93-IV [2B] (Queensland clone); ST5-IV [2B]; ST45-V [5C2&5]; ST1-IV [2B]; ST30-IV [2B]; ST97-IV [2B]; ST953-IV [2B]; and ST8-IV [2B]. As CA-MRSA is well established in the Australian community, it is important to monitor antimicrobial resistance patterns in community- and healthcare-associated SAB as this information will guide therapeutic practices in treating S. aureus bacteraemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Staphylococcal InfectionsMethicillin-Resistant Staphylococcus aureusBacteremiaCross InfectionAnti-Infective AgentsHumansStaphylococcus aureusAnti-Bacterial AgentsAgarMethicillinAustraliaDrug Resistance, BacterialErythromycinCiprofloxacinGentamicinsTetracycline

Stichwörter der Autor:innen

Australian Group on Antimicrobial Resistance (AGAR)antimicrobial resistance surveillanceStaphylococcus aureusmethicillin-susceptible Staphylococcus aureus (MSSA)methicillinresistant Staphylococcus aureus (MRSA)bacteraemia

Substanzen

Anti-Bacterial AgentsAgarMethicillinAnti-Infective AgentsErythromycinCiprofloxacinGentamicinsTetracycline

Autor:innen und Institutionen

  • Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospita…
  • Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia; Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australi…
  • Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia.

Zitieren

APA

Coombs, G. W., Daley, D. A., Shoby, P., & Mowlaboccus, S. (2023). Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome - Program (ASSOP) Bloodstream Infection Annual Report 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2023.47.67

Vancouver

Coombs GW, Daley DA, Shoby P, Mowlaboccus S. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome - Program (ASSOP) Bloodstream Infection Annual Report 2022. Communicable Diseases Intelligence. 2023. doi:10.33321/cdi.2023.47.67

BibTeX
@article{Coombs2023,
  author = {Coombs, Geoffrey W and Daley, Denise A and Shoby, Princy and Mowlaboccus, Shakeel},
  title = {Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome - Program (ASSOP) Bloodstream Infection Annual Report 2022},
  journal = {Communicable Diseases Intelligence},
  year = {2023},
  doi = {10.33321/cdi.2023.47.67}
}
Kostenlos starten →